A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial
Thomas J. Povsic, John H. Alexander(Ohio State University Hospital), Roxana Mehran(Mount Sinai Hospital), Jan H. Cornel(Brigham and Women's Hospital), Christopher E. Buller(Teleflex (United States)), Gilles Montalescot(Maastricht University Medical Centre), John P. Vavalle(Clinical Research Institute), Michael Ring(Providence Sacred Heart Medical Center), Steven L. Zelenkofske(Novartis (Switzerland)), Nicolas Delarche(Association François Aupetit), Jarosław D. Kasprzak(Medical University of Lodz), Uwe Zeymer(University of Freiburg), Richard C. Becker(Clinical Research Institute), Christoph Bode(University Medical Center Freiburg), Madhu K. Natarajan(Population Health Research Institute), Andrzej Rynkiewicz, Laura H. Aberle(Clinical Research Institute), Mauricio G. Cohen(Santa Ana College)
Cited by 108
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
|Circulation|2011|3.3k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k